Most Blood Cancer Drug Trials Are Not Randomized, Use Surrogate Endpoints
Of more than 2500 trials analyzed, 21% were randomized.
Lymphoma
Obinutuzumab With ICE Chemotherapy Well-Tolerated in Young Patients With Burkitt Lymphoma
Researchers sought to determine whether chemoimmunotherapy with obinutuzumab, ifosfamide, carboplatin, and etoposide would be effective in young patients with Burkitt lymphoma.
Allo-HSCT May Be Effective for Patients With Hepatosplenic T-Cell Lymphoma
Researchers sought to determine whether allo-HSCT would be helpful in treating patients with hepatosplenic T-cell lymphoma.
Vaccine-Induced Responses to Omicron, Delta Impaired in Non-Hodgkin Lymphoma Patients
Of the NHL patients with neutralizing antibodies against the WA1/2020 SARS-CoV-2 strain, 70% had antibodies against the delta variant, and 33% had antibodies against the omicron variant.
Promising Early Results Seen With a Bispecific Antibody-NK Cell Construct in CD30-Positive Lymphomas
Researchers sought to determine whether treatment of CD30-positive lymphomas with an innate cell engager would be effective.
Yescarta Approved for Second-Line Treatment of Large B-Cell Lymphoma
The approval was based on data from the phase 3 ZUMA-7 trial.
Bone Marrow Infiltration a Risk Factor for Infusion-Related Reactions in B-Cell NHL
A retrospective study of patient data sought to determine if bone marrow infiltration is linked to adverse effect severity in patients with CD20-positive B-NHL.
Platelet, Hemoglobin Levels Related to COVID-19 Mortality in Hematologic Malignancies
A study suggests low platelet or low hemoglobin levels may be factors linked to COVID-19 mortality in patients with hematologic malignancies.
Geriatric Assessment Better Than Chronologic Age for Measuring Health-Related Quality of Life in NHL
A prospective study sought to determine the value of geriatric assessment in patients with non-Hodgkin lymphoma, compared with assessment based on chronological age.
Analysis Defines Impact of Frailty on Outcomes in Lymphoma
Researchers conducted a secondary analysis of data from the phase 3 LY.12 clinical trial to measure effect of frailty on outcomes for patients with lymphoma.
- Loading...
Loading...
Next post in ASH 2021
Loading... 
Loading...